Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years

Abstract Objectives Gonadotropin-releasing hormone agonist treatment is important for optimal growth in girls with central precocious puberty (CPP). Data are lacking regarding benefit to height outcome when started after chronological age (CA) of 7 years, and if continued beyond CA 10 years or bone (BA) 12 years. Methods Forty-eight CPP were treated monthly leuprolide depot. Change predicted adult (PAH) during was assessed. Changes PAH velocity compared between initiating at <7 vs. ≥7 BA ≥12 <12 Results Mean baseline 6.8 BA, 10.2 years; PAH, 156.4 cm. BA/CA ratio decreased from pretreatment values, averaging 1.5 1.2 the end treatment. Proportion >5 cm change similar, increased throughout most girls, regardless initiation. increase 16/19 who also 16/22 Conclusions improved initiated It improve longer treatment, even past which suggests that no absolute limit should define initiation Treatment plans need be individualized, neither nor cessation based on alone.